Artivion, Inc. $AORT Position Trimmed by Deutsche Bank AG

Deutsche Bank AG trimmed its holdings in shares of Artivion, Inc. (NYSE:AORT) by 12.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,539 shares of the company’s stock after selling 4,443 shares during the period. Deutsche Bank AG owned about 0.08% of Artivion worth $800,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AORT. Peregrine Capital Management LLC acquired a new position in Artivion in the 1st quarter worth approximately $7,650,000. Point72 Asset Management L.P. bought a new position in shares of Artivion during the 4th quarter valued at $5,573,000. First Trust Advisors LP bought a new position in shares of Artivion during the 4th quarter valued at $4,771,000. Thornburg Investment Management Inc. bought a new position in Artivion in the 1st quarter worth $3,261,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Artivion in the 1st quarter worth $3,162,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on AORT. Citizens Jmp upgraded shares of Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th. LADENBURG THALM/SH SH lowered shares of Artivion from a “buy” rating to a “neutral” rating and lifted their target price for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. Needham & Company LLC boosted their price target on shares of Artivion from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday. Wall Street Zen upgraded shares of Artivion from a “hold” rating to a “buy” rating in a research report on Monday. Finally, Canaccord Genuity Group boosted their target price on shares of Artivion from $35.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Artivion presently has an average rating of “Buy” and an average target price of $40.63.

Artivion Stock Down 2.9%

Artivion stock opened at $43.53 on Tuesday. The stock has a market capitalization of $2.05 billion, a PE ratio of -103.64 and a beta of 1.64. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $45.07. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52. The company has a 50 day moving average of $33.95 and a 200-day moving average of $28.92.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.13. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The company had revenue of $112.97 million during the quarter, compared to analysts’ expectations of $107.96 million. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In related news, SVP Marshall S. Stanton sold 26,132 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $28.44, for a total transaction of $743,194.08. Following the completion of the transaction, the senior vice president owned 79,200 shares in the company, valued at approximately $2,252,448. This represents a 24.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John E. Davis sold 10,802 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total transaction of $471,723.34. Following the transaction, the insider owned 208,778 shares of the company’s stock, valued at $9,117,335.26. The trade was a 4.92% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 87,790 shares of company stock worth $3,190,959. Company insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.